<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">OR</journal-id>
<journal-title-group>
<journal-title>Oncology Reports</journal-title></journal-title-group>
<issn pub-type="ppub">1021-335X</issn>
<issn pub-type="epub">1791-2431</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/or.2012.2004</article-id>
<article-id pub-id-type="publisher-id">or-28-05-1845</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Proteomic differential display identifies upregulated vinculin as a possible biomarker of pancreatic cancer</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>WANG</surname><given-names>YUFENG</given-names></name><xref rid="af1-or-28-05-1845" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>KURAMITSU</surname><given-names>YASUHIRO</given-names></name><xref rid="af1-or-28-05-1845" ref-type="aff">1</xref><xref ref-type="corresp" rid="c1-or-28-05-1845"/></contrib>
<contrib contrib-type="author">
<name><surname>UENO</surname><given-names>TOMIO</given-names></name><xref rid="af2-or-28-05-1845" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>SUZUKI</surname><given-names>NOBUAKI</given-names></name><xref rid="af2-or-28-05-1845" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>YOSHINO</surname><given-names>SHIGEFUMI</given-names></name><xref rid="af2-or-28-05-1845" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>IIZUKA</surname><given-names>NORIO</given-names></name><xref rid="af2-or-28-05-1845" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>ZHANG</surname><given-names>XIULIAN</given-names></name><xref rid="af3-or-28-05-1845" ref-type="aff">3</xref></contrib>
<contrib contrib-type="author">
<name><surname>AKADA</surname><given-names>JUNKO</given-names></name><xref rid="af1-or-28-05-1845" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>OKA</surname><given-names>MASAAKI</given-names></name><xref rid="af2-or-28-05-1845" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>NAKAMURA</surname><given-names>KAZUYUKI</given-names></name><xref rid="af1-or-28-05-1845" ref-type="aff">1</xref></contrib></contrib-group>
<aff id="af1-or-28-05-1845">
<label>1</label>Department of Biochemistry and Functional Proteomics, Yamaguchi University Graduate School of Medicine, Ube, Japan</aff>
<aff id="af2-or-28-05-1845">
<label>2</label>Department of Digestive Surgery of Applied Molecular Bioscience, Yamaguchi University Graduate School of Medicine, Ube, Japan</aff>
<aff id="af3-or-28-05-1845">
<label>3</label>The Institute of Human Nutrition, Medical College of Qingdao University, Qingdao, P.R. China</aff>
<author-notes>
<corresp id="c1-or-28-05-1845"><italic>Correspondence to:</italic> Dr Yasuhiro Kuramitsu, Department of Biochemistry and Functional Proteomics, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755&#x02013;8505, Japan, E-mail: <email>climates@yamaguchi-u.ac.jp</email></corresp></author-notes>
<pub-date pub-type="ppub">
<month>11</month>
<year>2012</year></pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>08</month>
<year>2012</year></pub-date>
<volume>28</volume>
<issue>5</issue>
<fpage>1845</fpage>
<lpage>1850</lpage>
<history>
<date date-type="received">
<day>06</day>
<month>03</month>
<year>2012</year></date>
<date date-type="accepted">
<day>02</day>
<month>05</month>
<year>2012</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2012, Spandidos Publications</copyright-statement>
<copyright-year>2012</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions>
<abstract>
<p>Pancreatic cancer (PC) is characterized by rapid tumor spread, and very few patients with PC survive for more than 5 years. It is imperative to discover additional diagnostic biomarkers or specific therapeutic targets in order to improve the treatment of patients with PC. In search for useful biomarkers, we analyzed ten pairs of non-cancerous and cancer tissues from patients with PC by two-dimensional gel electrophoresis (2-DE). Nineteen protein spots showed differential expression on 2-DE gels between the cancer and non-cancerous tissues. Six upregulated protein spots were identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as calreticulin, glutathione synthetase, stathmin, vinculin, &#x003B1;-enolase and glyceraldehyde-3-phosphate dehydrogenase. Western blotting demonstrated that vinculin was predominantly expressed in the pancreatic cancer tissues compared with to non-cancerous tissues. Our findings indicate that vinculin may be a clinically useful biomarker of PC.</p></abstract>
<kwd-group>
<kwd>two-dimensional gel electrophoresis</kwd>
<kwd>liquid chromatography-tandem mass spectrometry</kwd>
<kwd>pancreatic cancer</kwd>
<kwd>vinculin</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Prognosis of patients with pancreatic cancer (PC) is poor because of belated diagnosis and lack of effective therapies. This disease is characterized by rapid tumor spread, and the median survival is less than 12 months with an overall 5-year survival rate of &lt;5&#x00025; (<xref rid="b1-or-28-05-1845" ref-type="bibr">1</xref>). It is imminent therefore to find more effective biomarkers for the diagnosis of patients with pancreatic cancer and to clarify the biological characteristics of rapid aggressiveness of PC.</p>
<p>In recent years, proteomics has been widely applied to the identification of candidate biomarkers and therapeutic targets in various cancers (<xref rid="b2-or-28-05-1845" ref-type="bibr">2</xref>&#x02013;<xref rid="b5-or-28-05-1845" ref-type="bibr">5</xref>). Two-dimensional gel electrophoresis (2-DE) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) are the major proteomics techniques, which are utilized in analyzing proteins comprehensively.</p>
<p>The proteomics technology is an ideal option for finding biomarkers and therapeutic targets in cancer. By applying 2-DE and LC-MS/MS combined with western blotting, we found six differentially expressed proteins between pancreatic cancerous and non-cancerous tissues, and among them vinculin was identified as a potential biomarker for PC diagnosis or prognosis.</p></sec>
<sec sec-type="methods">
<title>Materials and methods</title>
<sec>
<title>Pancreatic tissues and sample preparation</title>
<p>Thirty pairs of non-cancerous and cancerous pancreatic tissues were obtained from 30 patients (<xref rid="tI-or-28-05-1845" ref-type="table">Table I</xref>) who underwent resection of pancreas with diagnosis of pancreatic cancer at the Department of Surgery II, Yamaguchi University Hospital.</p>
<p>None of the patients received any preoperative therapy. Written informed consent was obtained from all patients before surgery. Tissues were obtained immediately after surgery and stored at &#x02212;80&#x000B0;C until use. The study protocol was approved by the Institutional Review Board for Human Use of the Yamaguchi University School of Medicine. The tissues were homogenized in lysis buffer (1&#x00025; NP-40, 1 mM sodium vanadate, 1 mM PMSF, 10 mM NaF, 10 mM EDTA, 50 mM Tris, 165 mM NaCl, 10 &#x003BC;g/ml leupeptin, and 10 &#x003BC;g/ml aprotinin) on ice (<xref rid="b5-or-28-05-1845" ref-type="bibr">5</xref>). Suspensions were incubated for 2 h at 4&#x000B0;C, and the supernatants were stored at &#x02212;80&#x000B0;C until they were used as samples. Ten pairs of samples were used for 2-DE, and twenty pairs for western blotting.</p></sec>
<sec>
<title>Two-dimensional gel electrophoresis (2-DE)</title>
<p>As the first dimension, isoelectric focusing (IEF) was conducted in an IPGphor 3 IEF unit (GE Healthcare, Buckinghamshire, UK) on 11-cm and pH 3&#x02013;10 linear gradient IPG strips (Bio-Rad, Hercules, CA, USA) at 50 &#x003BC;A/strip. Protein (80 &#x003BC;g) was used for each 2-DE. Samples were mixed with 200 &#x003BC;l of rehydration buffer &#x0005B;8 M urea, 2&#x00025; CHAPS, 0.01&#x00025; bromophenol blue, 1.2&#x00025; Destreak reagent (GE Healthcare)&#x0005D; and 0.5&#x00025; IPG buffer, and loaded in the IPGphor strip holder. The strips were then focused by the following program: rehydration for 10 h (no voltage); 0&#x02013;500 V for 4 h; 500&#x02013;1,000 V for 1 h; 1,000&#x02013;8,000 V for 4 h; 8,000 V for 20 min; and the final phase of 500 V from 20,000&#x02013;30,000 Vh (<xref rid="b6-or-28-05-1845" ref-type="bibr">6</xref>). After IEF, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed on a precast polyacrylamide gel with a linear concentration gradient of 5&#x02013;20&#x00025; (Bio-Rad) (<xref rid="b7-or-28-05-1845" ref-type="bibr">7</xref>). The IPG strips were first equilibrated in equilibration buffer 1 (6 M urea, 0.5 M Tris-HCl, pH 8.8, 30&#x00025; glycerol, 2&#x00025; SDS, 2&#x00025; 2-ME) for 10 min, and further in equilibration buffer 2 (6 M urea, 0.5 M Tris-HCl, pH 8.8, 30&#x00025; glycerol, 2&#x00025; SDS, 2.5&#x00025; iodoacetamide) for 10 min. The IPG strips were then transferred onto the gels, which were run at 200 V (<xref rid="b8-or-28-05-1845" ref-type="bibr">8</xref>). Each sample was replicated three times to ensure protein pattern reproducibility.</p></sec>
<sec>
<title>Fluorescence staining</title>
<p>The SDS-PAGE gels were fixed with 40&#x00025; ethanol and 10&#x00025; acetic acid for 2.5 h. The gels were then treated with a fluorescent gel staining, Flamingo&#x02122; Fluorescent Gel Stain (Bio-Rad), for 18 h (<xref rid="b9-or-28-05-1845" ref-type="bibr">9</xref>). The stained gels were washed with Milli-Q water 3 times, for 5 min each. These experimental procedures were carried out on a shaker.</p></sec>
<sec>
<title>Image analysis and spot picking</title>
<p>The gels were scanned by using the ProXpress 2-D Proteomic Imaging System (PerkinElmer, Waltham, MA, USA) and then analyzed by using the Progenesis SameSpots software (Nonlinear Dynamics, Newcastle, UK) following the user manual. After image analysis, the gels were stained with See Pico&#x02122; (Benebiosis Co., Ltd., Seoul, Korea) overnight (<xref rid="b10-or-28-05-1845" ref-type="bibr">10</xref>). The selected protein spots that displayed different intensities were cut from the gels and subjected to mass spectrometry (MS) analysis.</p></sec>
<sec>
<title>In-gel digestion</title>
<p>The gel pieces were destained by rinsing three times in 60&#x00025; methanol, 0.05 M ammonium bicarbonate, and 5 mM DTT for 15 min. The sample in the gel piece was reduced twice in 50&#x00025; methanol, 0.05 M ammonium bicarbonate, and 5 mM DTT for 10 min. The gel pieces were dehydrated twice in 100&#x00025; acetonitrile (ACN) for 30 min. Enzyme digestion was carried out with an in-gel digestion reagent containing 10 &#x003BC;g/ml sequencing-grade-modified trypsin (Promega Corporation, Madison, WI, USA) in 30&#x00025; ACN, 0.05 M ammonium bicarbonate, and 5 mM DTT at 30&#x000B0;C for 16 h. The samples were lyophilized overnight with the use of Labconco Lyph-lock 1L Model 77400 (Labconco, Kansas, MO, USA).</p></sec>
<sec>
<title>LC-MS/MS analysis</title>
<p>The lyophilized samples were dissolved in 15 &#x003BC;l of 0.1&#x00025; formic acid, and then analyzed by using the LC-MS/MS system. Peptide sequencing of identified protein spots was carried out by using LC-MS/MS with a Spectrum Mill MS Proteomics Workbench (Agilent Technologies, Palo Alto, CA, USA). Fifteen microliters of each sample was injected and placed into separated columns (Zorbax 300SB-C18, 75 &#x003BC;m, 150 mm, Agilent Technologies). The Agilent 1100 capillary pump was operated in the following conditions: solvent A, 0.1&#x00025; formic acid; solvent B, ACN in 0.1&#x00025; formic acid; column flow, 0.3 &#x003BC;l/min for primary flow, otherwise 300 &#x003BC;l/min; gradient, 0&#x02013;5 min 2&#x00025; B and 60 min 60&#x00025; B; stop time: 60 min. Proteins were identified in the Agilent Spectrum Mill MS Proteomics Workbench against the Swiss-Prot protein database search engine (<ext-link xlink:href="http://kr.expasy.org/sprot/" ext-link-type="uri">http://kr.expasy.org/sprot/</ext-link>) and MASCOT MS/MS Ions Search engine (<ext-link xlink:href="http://www.matrixscience.com/search_form_select.html" ext-link-type="uri">http://www.matrixscience.com/search_form_select.html</ext-link>). Standards for induction of candidate proteins were set as follows: filter by protein score &gt;10.0, and filter peptide by score &gt;8 (percent scored peak intensity).</p></sec>
<sec>
<title>Western blotting</title>
<p>The samples were separated by electrophoresis with SDS-PAGE gels and then transferred onto PVDF membranes at 90 mA for 78 min. The membranes were blocked overnight with TBS containing 5&#x00025; milk at 4&#x000B0;C (<xref rid="b11-or-28-05-1845" ref-type="bibr">11</xref>). They were incubated with the primary antibody against vinculin (anti-vinculin mouse monoclonal antibody, Sigma, St. Louis, MO, USA; 1:10,000), &#x003B1;-enolase (anti-enolase goat polyclonal antibody, Santa Cruz Biotechnology, Inc., Santa Cruz, CA; 1:1,000) and actin (anti-actin goat polyclonal antibody, Santa Cruz Biotechnology, Inc.; 1:200). The membranes were incubated with the secondary antibody conjugated with horseradish peroxidase (1:10,000) for 1 h at room temperature after washing three times with TBS containing Tween-20 and once with TBS. The membranes were treated with the ImmunoStar<sup>&#x000AE;</sup> LD chemiluminescent reagent (Wako Pure Chemical Industries Ltd., Osaka, Japan), and protein spots were detected by using the Image Reader LAS-1000 Pro (Fujifilm Corporation, Tokyo, Japan).</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>Detection of protein spots in pancreatic cancerous and non-cancerous tissues on 2-DE gels</title>
<p>2-DE gels were treated with a fluorescent gel stain, and then differences in the spot intensities between the tissues from pancreatic cancer and non-cancerous were analyzed and quantified by using the Progenesis SameSpots software. The results are summarized in <xref rid="tII-or-28-05-1845" ref-type="table">Table II</xref>. At least 260 protein spots were matched on each 2-DE gel. Six upregulated spots (spots 1&#x02013;6) were displayed on 2-DE gel with cancerous tissues at &gt;1.5-fold higher intensity (<xref rid="f1-or-28-05-1845" ref-type="fig">Fig. 1</xref>). The protein expression levels were elevated significantly (P&lt;0.05) in cancerous tissues when compared to paired non-cancerous tissues (<xref rid="f2-or-28-05-1845" ref-type="fig">Fig. 2</xref>).</p></sec>
<sec>
<title>Identification of proteins by LC-MS/MS</title>
<p>The samples were digested with trypsin and then analyzed by using LC-MS/MS system, which identified the six upregulated protein spots as calreticulin (spot 1), glutathione synthetase (spot 2), stathmin (spot 3), vinculin (spot 4), &#x003B1;-enolase (spot 5) and glyceraldehyde-3-phosphate dehydrogenase (spot 6). The spot numbers are the same as those in <xref rid="f1-or-28-05-1845" ref-type="fig">Fig. 1</xref>. MS/MS data of these proteins are summarized in <xref rid="tII-or-28-05-1845" ref-type="table">Table II</xref>.</p></sec>
<sec>
<title>Western blot analysis of vinculin and &#x003B1;-enolase</title>
<p>There are still no reports regarding overexpression of vinculin in PC and its importance for cell adhesion and migration (<xref rid="b12-or-28-05-1845" ref-type="bibr">12</xref>,<xref rid="b13-or-28-05-1845" ref-type="bibr">13</xref>). Twenty pairs of pancreatic cancerous and non-cancerous tissues were analyzed by western blotting with anti-vinculin antibody, and the different intensities of the bands between cancerous and non-cancerous tissues were analyzed by the Student&#x02019;s t-test (<xref rid="f3-or-28-05-1845" ref-type="fig">Fig. 3A</xref>). The mean intensities of the bands of cancerous and non-cancerous tissue samples were 125.2 and 66.4, respectively (<xref rid="f3-or-28-05-1845" ref-type="fig">Fig. 3A</xref>). Four pairs of cancerous and non-cancerous tissues were used for western blotting, to demonstrate the upregulation of &#x003B1;-enolase (<xref rid="b14-or-28-05-1845" ref-type="bibr">14</xref>) as a positive control in cancerous tissues, compared to non-cancerous tissues (<xref rid="f3-or-28-05-1845" ref-type="fig">Fig. 3B</xref>). The appearance of vinculin on the 2-DE gels was located by 2-D western blotting (<xref rid="f4-or-28-05-1845" ref-type="fig">Fig. 4</xref>).</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>We identified six upregulated proteins, calreticulin, glutathione synthetase, stathmin, vinculin, &#x003B1;-enolase and glyceraldehyde-3-phosphate dehydrogenase, in pancreatic cancerous tissues, compared to non-cancerous tissues. In this study, we reported only on those increased in cancerous tissues because many of the decreased proteins may have been replaced by stromal cells. To the best of our knowledge, this is the first report suggesting that vinculin is a candidate biomarker of PC.</p>
<p>Vinculin is a highly conserved intracellular protein (~123.8 kDa) with an important role in the regulation of cell adhesion and migration (<xref rid="b12-or-28-05-1845" ref-type="bibr">12</xref>,<xref rid="b13-or-28-05-1845" ref-type="bibr">13</xref>). Bakolitsa <italic>et al</italic> have explained how vinculin regulates cell adhesion by their detailed protein structural analysis (<xref rid="b15-or-28-05-1845" ref-type="bibr">15</xref>). Highly metastatic cells have been reported to lack vinculin expression (<xref rid="b16-or-28-05-1845" ref-type="bibr">16</xref>,<xref rid="b17-or-28-05-1845" ref-type="bibr">17</xref>). Vinculin inhibits cell metastasis when transfected back into vinculin-null cells (<xref rid="b17-or-28-05-1845" ref-type="bibr">17</xref>). Evidence reveals that apoptosis is related to cell motility (<xref rid="b18-or-28-05-1845" ref-type="bibr">18</xref>,<xref rid="b19-or-28-05-1845" ref-type="bibr">19</xref>), and that vinculin regulates cell apoptosis and motility via controlling the ERK pathway (<xref rid="b18-or-28-05-1845" ref-type="bibr">18</xref>).</p>
<p>Paradoxically, our study demonstrated that vinculin, which usually behaves as a potent inhibitor to the survival and motility of cells (<xref rid="b16-or-28-05-1845" ref-type="bibr">16</xref>&#x02013;<xref rid="b18-or-28-05-1845" ref-type="bibr">18</xref>), was significantly overexpressed in pancreatic cancerous tissues. Our findings indicate that vinculin could be a useful biomarker of PC for its high specificity. Vinculin is well characterized by its intracellular connecting component within adhesion complexes (<xref rid="b16-or-28-05-1845" ref-type="bibr">16</xref>), but its functions remain unclear. A new report suggests that vinculin is a main driver gene of the 10q22 amplification in 10q22-amplified prostate carcinomas and that overexpression of vinculin may play an enhancing role in tumor cell proliferation during prostate cancer progression (<xref rid="b20-or-28-05-1845" ref-type="bibr">20</xref>). This may be explained by the alternative splicing of vinculin gene, resulting in the alteration of the vinculin function during prostate carcinogenesis (<xref rid="b21-or-28-05-1845" ref-type="bibr">21</xref>). Further studies are required to clarify whether vinculin overexpression contributes to PC progression by enhancing tumor cell proliferation, and to elucidate vinculin&#x02019;s action in PC. Additional studies must be conducted in order to identify post-transcriptional modifications of vinculin in PC. Our data sheds light on a new facet of vinculin; its function in PC progression.</p>
<p>A previous report demonstrated that vinculin is related to tumor-suppressing properties (<xref rid="b22-or-28-05-1845" ref-type="bibr">22</xref>). However, our findings revealed a different property of vinculin in PC and suggest that vinculin may play a significant role in the diagnosis or prognosis of PC.</p></sec></body>
<back>
<ack>
<title>Acknowledgements</title>
<p>We thank Ms. Yanome for proofreading the manuscript. This study was supported in part by a Grant-in-Aid from the Ministry of Health, Labor and Welfare of Japan (no. H20-Bio-005 to K.N.).</p></ack>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term id="G1">PC</term>
<def>
<p>pancreatic cancer</p></def></def-item>
<def-item>
<term id="G2">2-DE</term>
<def>
<p>two-dimensional gel electrophoresis</p></def></def-item>
<def-item>
<term id="G3">LC-MS/MS</term>
<def>
<p>liquid chromatography-tandem mass spectrometry</p></def></def-item></def-list></glossary>
<ref-list>
<title>References</title>
<ref id="b1-or-28-05-1845"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Thun</surname><given-names>MJ</given-names></name></person-group><article-title>Cancer statistics, 2009</article-title><source>CA Cancer J Clin</source><volume>59</volume><fpage>225</fpage><lpage>249</lpage><year>2009</year></element-citation></ref>
<ref id="b2-or-28-05-1845"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuramitsu</surname><given-names>Y</given-names></name><name><surname>Miyamoto</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Fujimoto</surname><given-names>M</given-names></name><name><surname>Ueda</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Hamano</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name></person-group><article-title>Proteomic differential display analysis identified upregulated astrocytic phosphoprotein PEA-15 in human malignant pleural mesothelioma cell lines</article-title><source>Proteomics</source><volume>9</volume><fpage>5078</fpage><lpage>5089</lpage><year>2009</year></element-citation></ref>
<ref id="b3-or-28-05-1845"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luk</surname><given-names>JM</given-names></name><name><surname>Lam</surname><given-names>CT</given-names></name><name><surname>Siu</surname><given-names>AF</given-names></name><name><surname>Lam</surname><given-names>BY</given-names></name><name><surname>Ng</surname><given-names>IO</given-names></name><name><surname>Hu</surname><given-names>MY</given-names></name><name><surname>Che</surname><given-names>CM</given-names></name><name><surname>Fan</surname><given-names>ST</given-names></name></person-group><article-title>Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values</article-title><source>Proteomics</source><volume>6</volume><fpage>1049</fpage><lpage>1057</lpage><year>2006</year></element-citation></ref>
<ref id="b4-or-28-05-1845"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>U</given-names></name><name><surname>Razawi</surname><given-names>H</given-names></name><name><surname>Hommer</surname><given-names>J</given-names></name><name><surname>Engelmann</surname><given-names>K</given-names></name><name><surname>Schwientek</surname><given-names>T</given-names></name><name><surname>M&#x000FC;ller</surname><given-names>S</given-names></name><name><surname>Baldus</surname><given-names>SE</given-names></name><name><surname>Patsos</surname><given-names>G</given-names></name><name><surname>Corfield</surname><given-names>AP</given-names></name><name><surname>Paraskeva</surname><given-names>C</given-names></name><name><surname>Hanisch</surname><given-names>FG</given-names></name></person-group><article-title>Differential expression proteomics of human colorectal cancer based on a syngeneic cellular model for the progression of adenoma to carcinoma</article-title><source>Proteomics</source><volume>10</volume><fpage>194</fpage><lpage>202</lpage><year>2010</year></element-citation></ref>
<ref id="b5-or-28-05-1845"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuramitsu</surname><given-names>Y</given-names></name><name><surname>Harada</surname><given-names>T</given-names></name><name><surname>Takashima</surname><given-names>M</given-names></name><name><surname>Yokoyama</surname><given-names>Y</given-names></name><name><surname>Hidaka</surname><given-names>I</given-names></name><name><surname>Iizuka</surname><given-names>N</given-names></name><name><surname>Toda</surname><given-names>T</given-names></name><name><surname>Fujimoto</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Sakaida</surname><given-names>I</given-names></name><etal/></person-group><article-title>Increased expression and phosphorylation of liver glutamine synthetase in well-differentiated hepatocellular carcinoma tissues from patients infected with hepatitis C virus</article-title><source>Electrophoresis</source><volume>27</volume><fpage>1651</fpage><lpage>1658</lpage><year>2006</year></element-citation></ref>
<ref id="b6-or-28-05-1845"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Kuramitsu</surname><given-names>Y</given-names></name><name><surname>Fujimoto</surname><given-names>M</given-names></name><name><surname>Naito</surname><given-names>S</given-names></name><name><surname>Oka</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name></person-group><article-title>Downregulation of two isoforms of ubiquitin carboxyl-terminal hydrolase isozyme L1 correlates with high metastatic potentials of human SN12C renal cell carcinoma cell clones</article-title><source>Electrophoresis</source><volume>29</volume><fpage>2651</fpage><lpage>2659</lpage><year>2008</year></element-citation></ref>
<ref id="b7-or-28-05-1845"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuramitsu</surname><given-names>Y</given-names></name><name><surname>Hayashi</surname><given-names>E</given-names></name><name><surname>Okada</surname><given-names>F</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Ueyama</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name></person-group><article-title>Proteomic analysis for nuclear proteins related to tumour malignant progression: a comparative proteomic study between malignant progressive cells and regressive cells</article-title><source>Anticancer Res</source><volume>30</volume><fpage>2093</fpage><lpage>2099</lpage><year>2010</year></element-citation></ref>
<ref id="b8-or-28-05-1845"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuramitsu</surname><given-names>Y</given-names></name><name><surname>Baron</surname><given-names>B</given-names></name><name><surname>Yoshino</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Yashiro</surname><given-names>M</given-names></name><name><surname>Hirakawa</surname><given-names>K</given-names></name><name><surname>Oka</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name></person-group><article-title>Proteomic differential display analysis shows up-regulation of 14&#x02013;3&#x02013;3 protein sigma in human scirrhous-type gastric carcinoma cells</article-title><source>Anticancer Res</source><volume>30</volume><fpage>4459</fpage><lpage>4465</lpage><year>2010</year></element-citation></ref>
<ref id="b9-or-28-05-1845"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuramitsu</surname><given-names>Y</given-names></name><name><surname>Taba</surname><given-names>K</given-names></name><name><surname>Ryozawa</surname><given-names>S</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Maehara</surname><given-names>S</given-names></name><name><surname>Maehara</surname><given-names>Y</given-names></name><name><surname>Sakaida</surname><given-names>I</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name></person-group><article-title>Identification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry</article-title><source>Anticancer Res</source><volume>30</volume><fpage>3367</fpage><lpage>3372</lpage><year>2010</year></element-citation></ref>
<ref id="b10-or-28-05-1845"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuramitsu</surname><given-names>Y</given-names></name><name><surname>Hayashi</surname><given-names>E</given-names></name><name><surname>Okada</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Ueyama</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name></person-group><article-title>Staining with highly sensitive Coomassie brilliant blue SeePico&#x02122; stain after Flamingo&#x02122; fluorescent gel stain is useful for cancer proteomic analysis by means of two-dimensional gel electrophoresis</article-title><source>Anticancer Res</source><volume>30</volume><fpage>4001</fpage><lpage>4005</lpage><year>2010</year></element-citation></ref>
<ref id="b11-or-28-05-1845"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori-Iwamoto</surname><given-names>S</given-names></name><name><surname>Kuramitsu</surname><given-names>Y</given-names></name><name><surname>Ryozawa</surname><given-names>S</given-names></name><name><surname>Mikuria</surname><given-names>K</given-names></name><name><surname>Fujimoto</surname><given-names>M</given-names></name><name><surname>Maehara</surname><given-names>S</given-names></name><name><surname>Maehara</surname><given-names>Y</given-names></name><name><surname>Okita</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Sakaida</surname><given-names>I</given-names></name></person-group><article-title>Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine</article-title><source>Int J Oncol</source><volume>31</volume><fpage>1345</fpage><lpage>1350</lpage><year>2007</year></element-citation></ref>
<ref id="b12-or-28-05-1845"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volberg</surname><given-names>T</given-names></name><name><surname>Geiger</surname><given-names>B</given-names></name><name><surname>Kam</surname><given-names>Z</given-names></name><name><surname>Pankov</surname><given-names>R</given-names></name><name><surname>Simcha</surname><given-names>I</given-names></name><name><surname>Sabanay</surname><given-names>H</given-names></name><name><surname>Coll</surname><given-names>JL</given-names></name><name><surname>Adamson</surname><given-names>E</given-names></name><name><surname>Ben-Ze&#x02019;ev</surname><given-names>A</given-names></name></person-group><article-title>Focal adhesion formation by F9 embryonal carcinoma cells after vinculin gene disruption</article-title><source>J Cell Sci</source><volume>108</volume><fpage>2253</fpage><lpage>2260</lpage><year>1995</year></element-citation></ref>
<ref id="b13-or-28-05-1845"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Baribault</surname><given-names>H</given-names></name><name><surname>Adamson</surname><given-names>ED</given-names></name></person-group><article-title>Vinculin knockout results in heart and brain defects during embryonic development</article-title><source>Development</source><volume>125</volume><fpage>327</fpage><lpage>337</lpage><year>1998</year></element-citation></ref>
<ref id="b14-or-28-05-1845"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikuriya</surname><given-names>K</given-names></name><name><surname>Kuramitsu</surname><given-names>Y</given-names></name><name><surname>Ryozawa</surname><given-names>S</given-names></name><name><surname>Fujimoto</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>S</given-names></name><name><surname>Oka</surname><given-names>M</given-names></name><name><surname>Hamano</surname><given-names>K</given-names></name><name><surname>Okita</surname><given-names>K</given-names></name><name><surname>Sakaida</surname><given-names>I</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name></person-group><article-title>Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry</article-title><source>Int J Oncol</source><volume>30</volume><fpage>849</fpage><lpage>855</lpage><year>2007</year></element-citation></ref>
<ref id="b15-or-28-05-1845"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakolitsa</surname><given-names>C</given-names></name><name><surname>Cohen</surname><given-names>DM</given-names></name><name><surname>Bankston</surname><given-names>LA</given-names></name><name><surname>Bobkov</surname><given-names>AA</given-names></name><name><surname>Cadwell</surname><given-names>GW</given-names></name><name><surname>Jennings</surname><given-names>L</given-names></name><name><surname>Critchley</surname><given-names>DR</given-names></name><name><surname>Craig</surname><given-names>SW</given-names></name><name><surname>Liddington</surname><given-names>RC</given-names></name></person-group><article-title>Structural basis for vinculin activation at sites of cell adhesion</article-title><source>Nature</source><volume>430</volume><fpage>583</fpage><lpage>586</lpage><year>2004</year></element-citation></ref>
<ref id="b16-or-28-05-1845"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000FC;diger</surname><given-names>M</given-names></name></person-group><article-title>Vinculin and alpha-catenin: shared and unique functions in adherens junctions</article-title><source>Bioessays</source><volume>20</volume><fpage>733</fpage><lpage>740</lpage><year>1998</year></element-citation></ref>
<ref id="b17-or-28-05-1845"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ED;guez Fern&#x000E1;ndez</surname><given-names>JL</given-names></name><name><surname>Geiger</surname><given-names>B</given-names></name><name><surname>Salomon</surname><given-names>D</given-names></name><name><surname>Sabanay</surname><given-names>I</given-names></name><name><surname>Z&#x000F6;ller</surname><given-names>M</given-names></name><name><surname>Ben-Ze&#x02019;ev</surname><given-names>A</given-names></name></person-group><article-title>Suppression of tumorigenicity in transformed cells after transfection with vinculin cDNA</article-title><source>J Cell Biol</source><volume>119</volume><fpage>427</fpage><lpage>438</lpage><year>1992</year></element-citation></ref>
<ref id="b18-or-28-05-1845"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subauste</surname><given-names>MC</given-names></name><name><surname>Pertz</surname><given-names>O</given-names></name><name><surname>Adamson</surname><given-names>ED</given-names></name><name><surname>Turner</surname><given-names>CE</given-names></name><name><surname>Junger</surname><given-names>S</given-names></name><name><surname>Hahn</surname><given-names>KM</given-names></name></person-group><article-title>Vinculin modulation of paxillin-FAK interactions regulates ERK to control survival and motility</article-title><source>J Cell Biol</source><volume>165</volume><fpage>371</fpage><lpage>381</lpage><year>2004</year></element-citation></ref>
<ref id="b19-or-28-05-1845"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frisch</surname><given-names>SM</given-names></name><name><surname>Francis</surname><given-names>H</given-names></name></person-group><article-title>Disruption of epithelial cell-matrix interactions induces apoptosis</article-title><source>J Cell Biol</source><volume>124</volume><fpage>619</fpage><lpage>626</lpage><year>1994</year></element-citation></ref>
<ref id="b20-or-28-05-1845"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz</surname><given-names>C</given-names></name><name><surname>Holz</surname><given-names>DR</given-names></name><name><surname>Oeggerli</surname><given-names>M</given-names></name><name><surname>Schneider</surname><given-names>S</given-names></name><name><surname>Gonzales</surname><given-names>IM</given-names></name><name><surname>Kiefer</surname><given-names>JM</given-names></name><name><surname>Zellweger</surname><given-names>T</given-names></name><name><surname>Bachmann</surname><given-names>A</given-names></name><name><surname>Koivisto</surname><given-names>PA</given-names></name><name><surname>Helin</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer</article-title><source>J Pathol</source><volume>223</volume><fpage>543</fpage><lpage>552</lpage><year>2011</year></element-citation></ref>
<ref id="b21-or-28-05-1845"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorsen</surname><given-names>K</given-names></name><name><surname>S&#x000F8;rensen</surname><given-names>KD</given-names></name><name><surname>Brems-Eskildsen</surname><given-names>AS</given-names></name><name><surname>Modin</surname><given-names>C</given-names></name><name><surname>Gaustadnes</surname><given-names>M</given-names></name><name><surname>Hein</surname><given-names>AM</given-names></name><name><surname>Kruh&#x000F8;ffer</surname><given-names>M</given-names></name><name><surname>Laurberg</surname><given-names>S</given-names></name><name><surname>Borre</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis</article-title><source>Mol Cell Proteomics</source><volume>7</volume><fpage>1214</fpage><lpage>1224</lpage><year>2008</year></element-citation></ref>
<ref id="b22-or-28-05-1845"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziegler</surname><given-names>WH</given-names></name><name><surname>Liddington</surname><given-names>RC</given-names></name><name><surname>Critchley</surname><given-names>DR</given-names></name></person-group><article-title>The structure and regulation of vinculin</article-title><source>Trends Cell Biol</source><volume>16</volume><fpage>453</fpage><lpage>460</lpage><year>2006</year></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-or-28-05-1845" position="float">
<label>Figure 1</label>
<caption>
<p>Two-dimensional gel electrophoresis images of pancreatic cancerous and non-cancerous tissues stained with Flamingo&#x02122; fluorescent gel stain. Proteins were separated on pH 3&#x02013;10 linear, immobilized pH gradient strips followed by 5&#x02013;20&#x00025; SDS-PAGE. Six spots showed enhanced intensity on gels of cancerous tissues (A) compared to non-cancerous tissues (B). They were numbered as spots 1&#x02013;6</p></caption>
<graphic xlink:href="OR-28-05-1845-g00.gif"/></fig>
<fig id="f2-or-28-05-1845" position="float">
<label>Figure 2</label>
<caption>
<p>Enhanced protein expressions of carlreticulin (spot 1), glutathione synthetase (spot 2), stathmin (spot 3), vinculin (spot 4), &#x003B1;-enolase (spot 5) and glyceraldehyde-3-phosphate dehydrogenase (spot 6) in pancreatic cancerous tissues. The graphs show the normalized intensity of each spot in cancerous (C) compared to non-cancerous (N) tissues (n&#x0003D;30, P&lt;0.05). Spot numbers are same as in <xref rid="f1-or-28-05-1845" ref-type="fig">Fig. 1</xref>.</p></caption>
<graphic xlink:href="OR-28-05-1845-g01.gif"/></fig>
<fig id="f3-or-28-05-1845" position="float">
<label>Figure 3</label>
<caption>
<p>Western-blot analyses of vinculin and &#x003B1;-enolase in pancreatic cancerous and non-cancerous tissues. (A) Tissues from 20 patients with pancreatic cancerous and paired non-cancerous tissues were used for western blotting with anti-vinculin antibody. The expression of vinculin was increased in pancreatic cancerous tissues (80&#x00025;). Intensities of the bands were compared between cancerous and non-cancerous tissues by Student&#x02019;s t-test (n&#x0003D;20, P&lt;0.001). The relative standard errors (SE) of cancerous and non-cancerous tissue samples were 8.438 and 7.695, respectively. Expressions of &#x003B1;-enolase (B) and actin (C) were confirmed by western blotting respectively; the intensity of each band of &#x003B1;-enolase was stronger in cancerous tissues than in non-cancerous tissues. N, non-cancerous tissues; C, cancerous tissues.</p></caption>
<graphic xlink:href="OR-28-05-1845-g02.gif"/></fig>
<fig id="f4-or-28-05-1845" position="float">
<label>Figure 4</label>
<caption>
<p>Two-dimensional (2-D) western blotting of vinculin in pancreatic cancerous tissues. Two-dimensional western blotting was performed on a pair of samples on pH 3&#x02013;10 linear, which confirmed the locations of vinculin on PVDF membranes. The upregulated spot of vinculin was observed in cancerous tissue, compared to non-cancerous tissues.</p></caption>
<graphic xlink:href="OR-28-05-1845-g03.gif"/></fig>
<table-wrap id="tI-or-28-05-1845" position="float">
<label>Table I</label>
<caption>
<p>Clinicopathological parameters of patients with pancreatic cancer.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom">No.</th>
<th align="center" valign="bottom">Age</th>
<th align="center" valign="bottom">Gender</th>
<th align="center" valign="bottom">TNM stage</th>
<th align="center" valign="bottom">Tumor grade</th></tr></thead>
<tbody>
<tr>
<td align="left" valign="top">1<xref rid="tfn1-or-28-05-1845" ref-type="table-fn">a</xref></td>
<td align="center" valign="top">79</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">III</td>
<td align="left" valign="top">Moderately differentiated</td></tr>
<tr>
<td align="left" valign="top">2<xref rid="tfn1-or-28-05-1845" ref-type="table-fn">a</xref></td>
<td align="center" valign="top">67</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">III</td>
<td align="left" valign="top">Moderately differentiated</td></tr>
<tr>
<td align="left" valign="top">3<xref rid="tfn1-or-28-05-1845" ref-type="table-fn">a</xref></td>
<td align="center" valign="top">54</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">III</td>
<td align="left" valign="top">Moderately differentiated</td></tr>
<tr>
<td align="left" valign="top">4<xref rid="tfn1-or-28-05-1845" ref-type="table-fn">a</xref></td>
<td align="center" valign="top">75</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">IVb</td>
<td align="left" valign="top">Poorly differentiated</td></tr>
<tr>
<td align="left" valign="top">5<xref rid="tfn1-or-28-05-1845" ref-type="table-fn">a</xref></td>
<td align="center" valign="top">71</td>
<td align="left" valign="top">Female</td>
<td align="left" valign="top">III</td>
<td align="left" valign="top">Well differentiated</td></tr>
<tr>
<td align="left" valign="top">6<xref rid="tfn1-or-28-05-1845" ref-type="table-fn">a</xref></td>
<td align="center" valign="top">58</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">IVb</td>
<td align="left" valign="top">Mucinous carcinoma</td></tr>
<tr>
<td align="left" valign="top">7<xref rid="tfn1-or-28-05-1845" ref-type="table-fn">a</xref></td>
<td align="center" valign="top">70</td>
<td align="left" valign="top">Female</td>
<td align="left" valign="top">III</td>
<td align="left" valign="top">Moderately differentiated</td></tr>
<tr>
<td align="left" valign="top">8<xref rid="tfn1-or-28-05-1845" ref-type="table-fn">a</xref></td>
<td align="center" valign="top">64</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">III</td>
<td align="left" valign="top">Moderately differentiated</td></tr>
<tr>
<td align="left" valign="top">9<xref rid="tfn1-or-28-05-1845" ref-type="table-fn">a</xref></td>
<td align="center" valign="top">61</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">IVa</td>
<td align="left" valign="top">Moderately differentiated</td></tr>
<tr>
<td align="left" valign="top">10<xref rid="tfn1-or-28-05-1845" ref-type="table-fn">a</xref></td>
<td align="center" valign="top">51</td>
<td align="left" valign="top">Female</td>
<td align="left" valign="top">II</td>
<td align="left" valign="top">Moderately differentiated</td></tr>
<tr>
<td align="left" valign="top">11</td>
<td align="center" valign="top">67</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">IVa</td>
<td align="left" valign="top">Well differentiated</td></tr>
<tr>
<td align="left" valign="top">12</td>
<td align="center" valign="top">60</td>
<td align="left" valign="top">Female</td>
<td align="left" valign="top">III</td>
<td align="left" valign="top">Moderately differentiated</td></tr>
<tr>
<td align="left" valign="top">13</td>
<td align="center" valign="top">48</td>
<td align="left" valign="top">Female</td>
<td align="left" valign="top">IVa</td>
<td align="left" valign="top">Moderately differentiated</td></tr>
<tr>
<td align="left" valign="top">14</td>
<td align="center" valign="top">73</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">IVa</td>
<td align="left" valign="top">Moderately differentiated</td></tr>
<tr>
<td align="left" valign="top">15</td>
<td align="center" valign="top">54</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">IVa</td>
<td align="left" valign="top">Moderately differentiated</td></tr>
<tr>
<td align="left" valign="top">16</td>
<td align="center" valign="top">57</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">IVb</td>
<td align="left" valign="top">Moderately differentiated</td></tr>
<tr>
<td align="left" valign="top">17</td>
<td align="center" valign="top">54</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">III</td>
<td align="left" valign="top">Moderately differentiated</td></tr>
<tr>
<td align="left" valign="top">18</td>
<td align="center" valign="top">74</td>
<td align="left" valign="top">Female</td>
<td align="left" valign="top">IVa</td>
<td align="left" valign="top">Poorly differentiated</td></tr>
<tr>
<td align="left" valign="top">19</td>
<td align="center" valign="top">72</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">III</td>
<td align="left" valign="top">Moderately differentiated</td></tr>
<tr>
<td align="left" valign="top">20</td>
<td align="center" valign="top">72</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">IVa</td>
<td align="left" valign="top">Well differentiated</td></tr>
<tr>
<td align="left" valign="top">21</td>
<td align="center" valign="top">76</td>
<td align="left" valign="top">Female</td>
<td align="left" valign="top">IVa</td>
<td align="left" valign="top">Moderately differentiated</td></tr>
<tr>
<td align="left" valign="top">22</td>
<td align="center" valign="top">73</td>
<td align="left" valign="top">Female</td>
<td align="left" valign="top">III</td>
<td align="left" valign="top">Papillary carcinoma</td></tr>
<tr>
<td align="left" valign="top">23</td>
<td align="center" valign="top">53</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">IVb</td>
<td align="left" valign="top">Well differentiated</td></tr>
<tr>
<td align="left" valign="top">24</td>
<td align="center" valign="top">69</td>
<td align="left" valign="top">Female</td>
<td align="left" valign="top">III</td>
<td align="left" valign="top">Moderately differentiated</td></tr>
<tr>
<td align="left" valign="top">25</td>
<td align="center" valign="top">79</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">IVb</td>
<td align="left" valign="top">Mucinous carcinoma</td></tr>
<tr>
<td align="left" valign="top">26</td>
<td align="center" valign="top">34</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">IVb</td>
<td align="left" valign="top">Acinor carcinoma</td></tr>
<tr>
<td align="left" valign="top">27</td>
<td align="center" valign="top">71</td>
<td align="left" valign="top">Female</td>
<td align="left" valign="top">III</td>
<td align="left" valign="top">Moderately differentiated</td></tr>
<tr>
<td align="left" valign="top">28</td>
<td align="center" valign="top">67</td>
<td align="left" valign="top">Female</td>
<td align="left" valign="top">IVa</td>
<td align="left" valign="top">Moderately differentiated</td></tr>
<tr>
<td align="left" valign="top">29</td>
<td align="center" valign="top">68</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">III</td>
<td align="left" valign="top">Moderately differentiated</td></tr>
<tr>
<td align="left" valign="top">30</td>
<td align="center" valign="top">60</td>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">IVb</td>
<td align="left" valign="top">Moderately differentiated</td></tr></tbody></table>
<table-wrap-foot><fn id="tfn1-or-28-05-1845">
<label>a</label>
<p>indicates samples were used in 2-DE analysis.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="tII-or-28-05-1845" position="float">
<label>Table II</label>
<caption>
<p>Upregulated proteins in pancreatic cancerous tissues.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom">Spot</th>
<th align="center" valign="bottom">Accession no.<xref rid="tfn2-or-28-05-1845" ref-type="table-fn">a</xref></th>
<th align="center" valign="bottom">pI<xref rid="tfn3-or-28-05-1845" ref-type="table-fn">b</xref></th>
<th align="center" valign="bottom">Mr (Da)<xref rid="tfn3-or-28-05-1845" ref-type="table-fn">b</xref></th>
<th align="center" valign="bottom">Spot intensity ratio</th>
<th align="center" valign="bottom">Frequency</th>
<th align="center" valign="bottom">Protein</th></tr></thead>
<tbody>
<tr>
<td align="left" valign="top">1</td>
<td align="center" valign="top">P27797</td>
<td align="center" valign="top">4.29</td>
<td align="right" valign="top">48141.8</td>
<td align="center" valign="top">2.10</td>
<td align="center" valign="top">9/10</td>
<td align="left" valign="top">Calreticulin</td></tr>
<tr>
<td align="left" valign="top">2</td>
<td align="center" valign="top">P48637</td>
<td align="center" valign="top">5.67</td>
<td align="right" valign="top">52385.1</td>
<td align="center" valign="top">1.50</td>
<td align="center" valign="top">7/10</td>
<td align="left" valign="top">Glutathione synthetase</td></tr>
<tr>
<td align="left" valign="top">3</td>
<td align="center" valign="top">P16949</td>
<td align="center" valign="top">5.76</td>
<td align="right" valign="top">17302.6</td>
<td align="center" valign="top">1.50</td>
<td align="center" valign="top">5/10</td>
<td align="left" valign="top">Stathmin</td></tr>
<tr>
<td align="left" valign="top">4</td>
<td align="center" valign="top">P18206</td>
<td align="center" valign="top">5.50</td>
<td align="right" valign="top">123800.0</td>
<td align="center" valign="top">1.50</td>
<td align="center" valign="top">8/10</td>
<td align="left" valign="top">Vinculin</td></tr>
<tr>
<td align="left" valign="top">5</td>
<td align="center" valign="top">P06733</td>
<td align="center" valign="top">7.01</td>
<td align="right" valign="top">47169.2</td>
<td align="center" valign="top">1.60</td>
<td align="center" valign="top">9/10</td>
<td align="left" valign="top">&#x003B1;-enolase</td></tr>
<tr>
<td align="left" valign="top">6</td>
<td align="center" valign="top">P04406</td>
<td align="center" valign="top">8.57</td>
<td align="right" valign="top">6053.4</td>
<td align="center" valign="top">1.70</td>
<td align="center" valign="top">7/10</td>
<td align="left" valign="top">Glyceraldehyde 3-phosphate dehydrogenase</td></tr></tbody></table>
<table-wrap-foot><fn id="tfn2-or-28-05-1845">
<label>a</label>
<p>Accession number derived from the protein database.</p></fn><fn id="tfn3-or-28-05-1845">
<label>b</label>
<p>Theoretical pI and molecular weight (Da) from the protein database.</p></fn></table-wrap-foot></table-wrap></floats-group></article>
